Kluyvera is a relatively newly described genus in the family Enterobacteriaceae that infrequently causes infections in humans. The organism has been isolated from various clinical specimens, but its significance has not been clearly established. In fact, it has been regarded alternatively as saprophytic, opportunistic, or pathogenic. Since the redefinition of this genus in 1981, case reports of diverse clinical infections occurring under various host conditions have been published. Here we present a critical review of all Kluyvera infections reported in the literature, along with our experience involving 5 additional cases. Most patients received prompt antimicrobial treatment on the basis of susceptibility testing, and overall the clinical outcomes were good. Antimicrobial agents active against most Kluyvera strains include third-generation cephalosporins, fluoroquinolones, and aminoglycosides. In contrast, the resistance to ampicillin, extended-spectrum penicillins, and first-and second-generation cephalosporins is significant. Kluyvera is a potentially virulent pathogen that deserves aggressive treatment designed with an awareness of the organism's antimicrobial resistance patterns.
Kluyvera is described infrequently in association with clinically significant infections. In the early 1980s, the organism was regarded mostly as a benign saprophyte that colonized predominantly the respiratory, gastrointestinal, or urinary tract [1] . More recently, however, diverse infections occurring under various host conditions have been reported. Most of these infections involved the gastrointestinal or urinary tract and the soft tissues. Bacteremia and other serious infections have also occurred. Here we review all Kluyvera infections recorded in the literature and report 5 cases that shed light on the importance of this organism as a cause of human disease.
METHODS
Our cases in which Kluyvera strains caused infection in humans were identified by a retrospective analysis of clinical microbiology laboratory records at the Texas Tech University Health Sciences Center and University Medical Center (Lubbock, Texas) from 1 January 1999 through 31 December 2000. The University Medical Center is a tertiary-care teaching institution with 357 beds that serves a population of 1.8 million. All cases of Kluyvera infection occurred sporadically and at various services in the institution. The organisms were isolated from urine and wound exudate samples by routine clinical microbiology methods. Identification to the species level and antimicrobial susceptibility testing was performed with MicroScan panels (Dade Behring). We also searched for Kluyvera-associated cases in the literature, using MEDLINE and the references listed in retrieved articles published since redefinition of the genus in 1981.
DISCUSSION
In 1936, Kluyver et al. [2] postulated that there may be a distinctive group of fermentative bacteria in the family Enterobacteriaceae. Twenty years later, Asai et al. [3] described a group of organisms they believed were identical to those postulated by Kluyver and proposed the genus name Kluyvera. However, in 1962, the same investigators proposed that the genus identification be eliminated, because, according to them, the organism was phenotypically identical to Escherichia [4] . Only since 1981, when Farmer et al. [1] redefined Kluyvera as a separate genus, using biochemical and DNA-DNA hybridization techniques, have more strains been recognized and more clinical experiences emerged from reports of infections caused by this organism. Kluyvera is a small, flagellated, motile gram-negative bacillus that clearly belongs to the family Enterobacteriaceae. The organism is distinguished from other related genera by its ability to use citrate and malonate, decarboxylate lysine, and ornithine and to produce large quantities of a-ketoglutaric acid during the fermentation of glucose. Kluyvera grows well in ordinary culture media, and its colonies resemble those of Escherichia [1] . No specific virulence factor has been identified, but like other Enterobacteriaceae, the organism has a lipopolysaccharide complex and surface antigens that may confer virulence. The genus has 3 species: Kluyvera ascorbata, the type species of the genus and the species most frequently isolated in clinical specimens; Kluyvera cryocrescens, a strain found predominantly in the environment; and Kluyvera species group 3, a strain infrequently isolated from any source. Kluyvera is present in the environment as free-living organisms in water, soil, sewage, hospital sinks, and food products of animal origin. In humans, it is usually isolated from sputum, urine, and stool samples [1, 5] . Kluyvera is part of the normal flora of the human digestive tract, but it is usually associated with low bacterial counts. This might explain why its isolation in clinical infections is rare. It is unknown whether Kluyvera infections are predominantly endogenous or environmentally acquired or whether both routes are equally important.
Early reports of Kluyvera infections regarded the organism mostly as a benign saprophyte that predominantly colonized the respiratory, urinary, or gastrointestinal tract [1, [6] [7] [8] . Since 1980, however, 22 clinically significant Kluyvera infections have been reported (table 1). In the study reported in 1981, Farmer et al. [1] noted the first 5 cases of Kluyvera bacteremia. Unfortunately, clinical information for these cases is not available. Since then, 6 additional cases of bloodstream infection have been reported [9] [10] [11] [12] [13] [14] . In 3 of these cases, the patients died [9] [10] [11] , and the cause of death was directly attributed to complications of Kluyvera sepsis in at least 1 of those 3 cases [11] . We are aware of 2 other fatal Kluyvera infections, which occurred in patients with peritonitis and intra-abdominal abscesses [15, 16] . Kluyvera has also caused infections with multiple organ and system involvement [10, 15] .
Only 3 reports of cases of Kluyvera pyelonephritis have been published [12, 17, 18] . Ortega et al. [19] described a young female patient whose urine culture was positive for K. cryocrescens and who had persistent proteinuria but no definite evidence of urinary tract infection. Only 2 investigators have implicated Kluyvera as a cause of diarrhea [7, 20] . The organism has also caused biliary tract infections [8, 14, 21] , post-traumatic urethrorectal fistula [18] , and soft-tissue infections [22, 23] .
Our experience involves 5 cases in which Kluyvera was pathogenic (table 1) and 2 cases in which colonization occurred (not included in table 1). K. ascorbata was isolated from all of these patients. Three patients had lower urinary tract infections, 1 had pyelonephritis, and 1 had a finger abscess. The clinical characteristics of these patients were typical for these infections. One of the lower urinary tract infections occurred in a pregnant woman. To our knowledge, lower urinary tract and pregnancyrelated Kluyvera infections have not been previously reported. In 2 other patients (not included in table 1), colonization or contamination of a burn wound and urine occurred after prolonged hospitalizations. These patients were also colonized by other organisms and recovered without specific treatment.
Even though most infections described to date have involved either the gastrointestinal or urinary tract or the soft tissues, it appears that no specific site of infection is favored by these bacteria. It is interesting that infections of the CNS or musculoskeletal system have not been reported. Infections caused by Kluyvera occur under as yet poorly defined host conditions, and no specific host defect has been identified. Because the few cases that have involved patients with malignancy, neutropenia, diabetes mellitus, or chronic liver or renal disease and patients who are pregnant, have used steroids, or have undergone surgery, trauma, or insertion of foreign material hardly define a predisposition, generalizations cannot be made. Moreover, infections at various sites and of wide-ranging severity have been described as occurring in subjects without identifiable underlying medical conditions or immune defects (table 1). To our knowledge, HIVrelated Kluyvera infections have not been reported.
Kluyvera may have a more pathogenic nature than previously believed. The organism is capable of causing severe infections even in immunocompetent individuals [17, 18, 21] ; fatalities attributed to Kluyvera have occurred [11, 15, 16] ; the organism has been isolated in pure cultures of blood and other normally sterile specimens from patients who have clinically significant infections [9] [10] [11] [12] [13] [14] [15] [16] ; it is capable of invading multiple organs and has a tendency to form abscesses [10, 15, 16] ; and clinical improvement is seen after specific treatment is instituted.
Limited information is available regarding the in vitro susceptibility profiles and clinical effectiveness of antimicrobials in Kluyvera infections. In 1981, Farmer et al. [1] reported the antimicrobial susceptibilities of 73 strains of K. ascorbata and 16 A strain isolated in 1 of our cases was resistant to amikacin, ciprofloxacin, and third-generation cephalosporins. Resistance to these agents has not been previously reported. Clinical experience with use of antimicrobials in the treatment of Kluyvera infections is limited to information derived from individual case reports. Most patients treated with agents that showed in vitro activity recovered (table 1) . No single antimicrobial or antimicrobial class should be considered to be the first choice. Apart from an agent's in vitro activity, factors to consider when selecting an antimicrobial regimen include a drug's bioavailability, induction of resistance, toxicity, and cost. This review suggests that the agents most consistently active in vitro against Kluyvera are third-generation cephalosporins, fluoroquinolones, aminoglycosides, imipenem, chloramphenicol, and nitrofurantoin. Most strains are resistant to ampicillin, first-and secondgeneration cephalosporins, and ticarcillin. Agents with variable activity include ampicillin-sulbactam, aztreonam, piperacillin, tetracycline, and trimethoprim-sulfamethoxazole (table 2) . We have to emphasize that the number of strains analyzed is small, and further in vitro data and clinical experience are needed before treatment recommendations can be made.
In summary, this review suggests that Kluyvera, although infrequently so, is a potentially dangerous pathogen in humans. The organism can cause diverse and sometimes severe clinical infections under as yet poorly defined host conditions. Identification of Kluyvera in the course of typical microbiology laboratory routines may be problematic, because its biochemical identification patterns are similar to those of other, related genera, which may result in underestimation of the true incidence of these infections. Increased awareness and a meticulous evaluation of the organism's growth and susceptibility patterns may aid in identification. A prompt identification of Kluyvera species in clinical infections is important, because adequate antimicrobial treatment usually results in recovery. Further data are needed to understand the pathogenicity, epidemiology, clinical manifestations, and antimicrobial treatment of such infections.
